October 01, 2016 4:03 AM ET


Company Overview of Milestone Pharmaceuticals Inc.

Company Overview

Milestone Pharmaceuticals Inc. operates as a cardiovascular drug development company that develops novel small molecule therapeutics. It offers a novel and potent short-acting calcium channel antagonist for the treatment of transient cardiovascular conditions, such as paroxysmal supraventricular tachycardia by the termination of acute episodes of atrial tachycardia in patients. The company was founded in 2005 and is based in Saint-Laurent, Canada.

1111 Dr.-Frederik-Philips Boulevard

Suite 420

Saint-Laurent, QC H4M 2X6


Founded in 2005





Key Executives for Milestone Pharmaceuticals Inc.

Chief Executive Officer and Director
Chief Medical Officer
Chief Medical Advisor
Age: 60
Vice President of Corporate Development
Vice President of Chemistry & Manufacturing
Compensation as of Fiscal Year 2016.

Milestone Pharmaceuticals Inc. Key Developments

Milestone Pharmaceuticals Inc. Presents at 18th Annual BIO CEO & Investor Conference 2016, Feb-08-2016 03:30 PM

Milestone Pharmaceuticals Inc. Presents at 18th Annual BIO CEO & Investor Conference 2016, Feb-08-2016 03:30 PM. Venue: The Waldorf Astoria, 301 Park Avenue, New York, New York, United States.

Milestone Pharmaceuticals Inc. Announces United States Adopted Name Approval of Generic Name "Etripamil" for Phase 2 Clinical Development Product

Milestone Pharmaceuticals Inc. announced that United States Adopted Name (USAN) Council recently adopted "etripamil" as the unique non-proprietary or generic name for MSP-2017. The purpose of the United States Adopted Names Council is to serve the health professions in the United States by selecting simple, informative, and unique nonproprietary names for drugs by establishing logical nomenclature classifications based on pharmacological and/or chemical relationships. Etripamil is being developed as a patient self-administered intranasal spray to terminate paroxysmal supraventricular tachycardia (PSVT) at the onset of episodes and is currently being evaluated in a Phase 2 clinical trial (NODE-1) in the United States and Canada. Etripamil is a novel and potent short-acting calcium channel antagonist intended for the treatment of patients with PSVT, a potentially debilitating cardiac arrhythmia. Phase 1 results showed that etripamil had a rapid onset and reached pharmacologically relevant plasma levels within 5 minutes of administration. Etripamil is designed to be short-acting and metabolized quickly after resolution of the PSVT episode to avoid the potential complications of current long-term therapies. Etripamil is intended to address an important unmet medical need in patients who demand a convenient, rapidly efficacious and safe self-administered product for the treatment of PSVT episodes in the home setting.

Milestone Pharmaceuticals Inc. Presents at BIO-Europe Spring 2016, Apr-05-2016 02:45 PM

Milestone Pharmaceuticals Inc. Presents at BIO-Europe Spring 2016, Apr-05-2016 02:45 PM. Venue: Kistamässan Convention Center, Stockholm, Sweden.

Similar Private Companies By Industry

Company Name Region
4everPets Ltd. Americas
9037136 Canada Inc. Americas
AAA Heidelberg Inc. Americas
Ab Biotech Inc. Americas
ABcann Medicinals Inc. Americas

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
NYC2012, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Milestone Pharmaceuticals Inc., please visit www.milestonepharma.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.